Skip to content

Clinical trials

Observational Prostatic Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Phase: Observational Country / region: United States Clear all

461 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20014
20028
20037
200413
200511
200613
200714
200816
200915
201014
201115
201217
201323
201421
201524
201620
201731
201822
201922
202024
202123
202214
202319
202417
202519
202616

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed222
Recruiting86
Terminated53
Active, not recruiting35
Unknown status27
Withdrawn24
Enrolling by invitation6
Not yet recruiting4
Suspended4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)28
Memorial Sloan Kettering Cancer Center22
M.D. Anderson Cancer Center18
Mayo Clinic15
Duke University12
Massachusetts General Hospital11
University of California, San Francisco9
Bayer8
Myriad Genetic Laboratories, Inc.8
H. Lee Moffitt Cancer Center and Research Institute7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms461
Breast Neoplasms70
Lung Neoplasms51
Neoplasms41
Colorectal Neoplasms30
Colonic Neoplasms28
Urinary Bladder Neoplasms24
Melanoma23
Ovarian Neoplasms23
Pancreatic Neoplasms22

Trials

Showing 1 to 25 of 461. Each trial links to its page on Pharma Observatory.

361 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.